Diligence memo · auto-generated · as of July 2, 2026
Alexza Pharmaceuticals Inc.
Alexza Pharmaceuticals Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Alexza Pharmaceuticals Inc. operates in Pharmaceuticals, based in MOUNTAIN VIEW.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Alexza Pharmaceuticals Inc. has raised $62M in disclosed capital across 7 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $25M on —.
Most recent recorded round closed around 2016-02-23.
Valuation (modeled)modeled
Provath models Alexza Pharmaceuticals Inc. at approximately $170M (range $11M–$654M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.25× the median modeled value of Series B Pharmaceuticals companies in 2016–2018 (40 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 92 months.
Last raise 10.4 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 34.8× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 85% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 66% of those peers.
Closest niche peers: LP Investors, LLC, GigaGen, Inc., Vitality Biopharma, Inc., Madrigal Pharmaceuticals, Inc., Slayback Pharma Ltd Liability Co.
Peoplefiled
19 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.